Q320 was a ray of sunshine for the US Spinal Cord Stimulation (SCS) market as revenues returned to almost pre-COVID levels according to SmartTRAK Financial Dashboard. Sequentially, US revenues bounced sharply from Q220. Although OUS revenues weren’t as sunny, WW SCS revenues recovered in Q320, jumping ~60% sequentially from Q220 revenues.
Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Spinal Cord Stimulation Market Recap* are:
- Complete SCS Market Overview and Highlights
- Abbott: Improved Visibility and Execution
- Medtronic: Continued Gains with DTM SCS
- BSX’s Balanced Procedure Recovery
- Nevro Omnia Helps Rebound
- Round up of Other SCS Companies
- Q320 Clinical/Regulatory News
Cases returned in Q320 as physicians addressed the backlog of SCS cases and focused on rescheduling canceled cases and moving patients and trials through the funnel to a permanent implant. However, COVID-19 cases are increasing around the globe, creating a dark cloud on the horizon that could soften the short-term recovery and the number of SCS cases performed in the next few quarters. Although many SCS cases are performed in ambulatory surgery centers, hospitals are seeing a rising number of COVID-19 patients and are beginning to place a hold on elective procedures to ensure there are ...
*The entire article, including revenue, shares and links can only be viewed by SmartTRAK subscribers to this module.